| ISA 2015 Amsterdam, The Netherlands |
|
|
|
last updated: December 2, 2013
|
 |
To access some of the content on athero.org
you must be a registered user and you must log on.
You can use the interface on the right side of this page to either log on or to register.
|
IAS - Pfizer IGCL Grant Opportunity - Request for Proposals (RFP)
Reducing Cardiovascular Risk Globally Through Improved Dyslipidemia Awareness and Treatment
The International Atherosclerosis Society (IAS) and Pfizer are collaborating to offer a new grant opportunity focused on improving care for patients with medium or high levels of cardiovascular risk, with a particular focus on dyslipidemia.
This RFP was issued by both organizations. The IAS is the lead organization for review and evaluation of applications. A review committee, led by the IAS, has begun the decision-making process to determine which proposals will receive funding. Grant funding will be provided by Pfizer. Collectively, up to $2 million is available for award.
Those Letters of Intent selected to submit a Full Proposal will be announced soon.
|
IAS Position Paper: Global Recommendations for the Management of Dyslipidemia.
The International Atherosclerosis Society (IAS) here updates its recommendations on treatment of high level of blood cholesterol and dyslipidemia for the purpose of reducing risk for atherosclerotic
cardiovascular disease (ASCVD). The Writing Panel, made of 15 internationally renowned experts and chaired by dr Scott M. Grundy, reviewed existing evidence-based recommendations
and consolidated them into an overall set of recommendations. For comments and suggestions please write us at positionpaper@athero.org.
|
This site is optimised for a min. 1024 x 768 pixels resolution and with best colors view (max 32 bit)
|
The International Atherosclerosis Society (IAS), incorporated in 1979, promotes, at an international level, the advancement of science, research and teaching in the field of atherosclerosis and related diseases.
|
|
| IAS Newsletter Editors & Website Editorial Board |
Editor-in-Chief
Scott M. Grundy, MD, PhD
Dallas, TX, USA
Associate Editors
Stefano Bellosta
Milan, Italy
Emanuela Folco
Milan, Italy
Ann Jackson
Houston, TX, USA
Commentary & Newsletter Editor
Yelonda Williams
Dallas, TX, USA
|
|
|
We are very excited about our new initiative with Pfizer's IGLC to provide funding for projects addressing how to improve care for patients with medium or high levels of cardiovascular risk, with a particular focus on dyslipidemia. 
